Singapore- Regeneron Pharmaceuticals and development partner Sanofi announce positive preliminary data from a Phase 1 clinical trial assessing cemiplimab in advanced non-small cell lung cancer (NSCLC). The results will be presented at ASCO in Chicago.

The overall response rate was 29% (n=6/21), all partial, and the disease control rate (responders + those with stable cancer) was 57% (n=12/21) as of the data cutoff date. Duration of response exceeded eight months in five of the six responders.

Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.